Compare Danaher Corporation (DHR) vs Freeport-McMoRan Inc (FCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Freeport-McMoRan Inc — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while Freeport-McMoRan Inc trades at $73.69 (market cap $102.16B). The key difference: Danaher Corporation is the larger of the two by market cap, and Freeport-McMoRan Inc pays the higher dividend (0.84%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Freeport-McMoRan Inc for 69 Days on average.
| DHR | FCX | |
|---|---|---|
Market Cap | $152.87B | $102.16B |
Volume | 5,228,698 | 9,047,971 |
Sector | Health | Basic Materials |
52-Week High | $242.05 | $79.91 |
52-Week Low | $161.91 | $38.65 |
Typical Hold Time | 69 Days | 69 Days |
Enterprise Value | $175.08B | $108.44B |
Dividend Yield | 0.74% | 0.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
FCX trades at $71.13, down 1.02% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.68 exceeding the $0.60 estimate. Revenue for 2025 was $25.92B, with net income of $2.20B and an 11.38% net margin. Analyst consensus is a Buy with a $73.27 price target, and recent news highlights copper demand growth driven by AI and data centers.
FCX presents a positive outlook supported by robust copper demand trends and expansion projects, though rising production costs and a bearish technical picture pose near-term risks. The stock offers potential upside to the consensus target, but investors should monitor cost pressures and quarterly execution against expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →
